Upstream Processing

Webinar Date/Time: Tue, Mar 17, 2026 11:00 AM EDT

Targeted integration enables predictable clonal cell lines, enhancing transgene control and accelerating biopharma cell line development.

Fluorescence spectroscopy with A-TEEM offers rapid, precise monitoring of cell culture media variability for improved biopharmaceutical quality control.

Webinar Date/Time: Wed, Oct 22, 2025 11:00 AM EDT

The inaugural BioPharma By the Numbers provides a data-driven look at how automation in bioprocessing is driving efficiency, reducing errors, and addressing capacity challenges.

New GS knockout CHO-K1 systems accelerate biologics manufacturing by improving yields, scalability, and flexibility for biopharma development programs.

Engineered biosynthetic pathways provide new avenues for accessing complex molecules.

Advanced technology platforms optimize the efficiencies and sustainability of single-use bioreactors, setting the scene for the next evolutionary step in biomanufacturing.

AnalytiChem has launched the Redipor line of ready-to-use culture media, which brings three well-known brands under one global brand.

This paper outlines a systematic approach to detecting contamination through process deviations, including changes in % dissolved oxygen, pH, and metabolic patterns.

Wider adoption of single-use technologies and systems is aligning with sustainability goals for the industry.

The addition of the two larger-volume bioreactor sizes to Cytiva’s Xcellerex X-platform portfolio will allow scientists and researchers to scale up from 50 L to 2000 L to meet growing demand for clinical trials and regulatory approved products.

Webinar Date/Time: Tue, Mar 4, 2025 11:00 AM EST

Cell-line engineering and media formulation improvements are leading to greater performance.

Enduro Genetics will use the funding to expand its cell programming technology for scalable biomanufacturing with microbial cells at its Copenhagen, Denmark site.

Optimizing the harvest of viral particles is important for the yield and purity of the final product.

Synthesis of DNA via cell-free methods has many benefits versus fermentation.

Webinar Date/Time: Thu, Dec 12, 2024 11:00 AM EST

Under a £15.7 million (US$20.7 million) investment, SEKISUI has expanded its UK site for clinical-grade drug substance manufacturing.

With financing led by OrbiMed, Novo Holdings, and Jeito Capital, Alentis Therapeutics will develop a pipeline of Claudin-1-targeted ADCs to treat solid tumors.

Webinar Date/Time: Thu, Nov 7, 2024 11:00 AM EDT

Space-time yield is a critical metric for comparison of upstream biomanufacturing processes and can be useful in reducing commercial production costs.

Webinar Date/Time: Thu, Oct 31, 2024 11:00 AM EDT

Webinar Date/Time: Wed, Oct 16, 2024 11:00 AM EDT

Stable cell line development can benefit from applying integrated analytical technologies.